<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1533022</PMID>
      <DateCompleted>
        <Year>1992</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0029-7844</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>79</Volume>
            <Issue>5 ( Pt 1)</Issue>
            <PubDate>
              <Year>1992</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Obstetrics and gynecology</Title>
          <ISOAbbreviation>Obstet Gynecol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial.</ArticleTitle>
        <Pagination>
          <StartPage>739</StartPage>
          <EndPage>742</EndPage>
          <MedlinePgn>739-42</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Gonadotropin-releasing hormone agonists vary in structure and route of administration. We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous leuprolide acetate as adjuncts to ovulation induction for in vitro fertilization (IVF). Forty-two patients entering their first cycle of IVF were randomized to receive either nafarelin acetate or leuprolide acetate. Patient characteristics in the two groups did not differ significantly, nor did cycle cancellation rates or outcome. There was no significant difference in patient response as indicated by follicular phase serum levels of estradiol (E2), FSH, or LH, luteal phase E2, and progesterone. Luteal phase progesterone-dependent endometrial protein was significantly lower in those taking nafarelin acetate, though it remained in the normal range. However, those receiving nafarelin acetate required significantly less human menopausal gonadotropin (hMG) and had significantly more embryos frozen for later transfer than those receiving leuprolide acetate. Intranasal nafarelin acetate can be used successfully in ovulation induction regimens that include GnRH agonists. The use of nafarelin acetate may decrease a patient's hMG requirement and increase the number of frozen embryos available for later transfer as compared with leuprolide acetate. Further studies are needed to optimize the dosing regimen.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Penzias</LastName>
            <ForeName>A S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shamma</LastName>
            <ForeName>F N</ForeName>
            <Initials>FN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gutmann</LastName>
            <ForeName>J N</ForeName>
            <Initials>JN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jones</LastName>
            <ForeName>E E</ForeName>
            <Initials>EE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>DeCherney</LastName>
            <ForeName>A H</ForeName>
            <Initials>AH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lavy</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Obstet Gynecol</MedlineTA>
        <NlmUniqueID>0401101</NlmUniqueID>
        <ISSNLinking>0029-7844</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33515-09-2</RegistryNumber>
          <NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EFY6W0M8TG</RegistryNumber>
          <NameOfSubstance UI="D016729">Leuprolide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Obstet Gynecol. 1992 Oct;80(4):727-9</RefSource>
          <PMID Version="1">1407904</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005307" MajorTopicYN="Y">Fertilization in Vitro</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005498" MajorTopicYN="N">Follicular Phase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016729" MajorTopicYN="N">Leuprolide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008183" MajorTopicYN="N">Luteal Phase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010062" MajorTopicYN="N">Ovulation Induction</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1992</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1992</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1992</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">1533022</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
